Joachim Deeg

Summary

Affiliation: Fred Hutchinson Cancer Research Center
Country: USA

Publications

  1. pmc Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and concurrent lymphoid malignancy
    Z Zimmerman
    Fred Hutchinson Cancer Research Center and University of Washington School of Medicine, Seattle, WA 98109 1024, USA
    Bone Marrow Transplant 47:804-9. 2012
  2. pmc Effect of intravenous coadministration of human stroma cell lines on engraftment of long-term repopulating clonal myelodysplastic syndrome cells in immunodeficient mice
    X Li
    1 Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA 2 School of Medicine, Jiangnan University, Wuxi, China
    Blood Cancer J 3:e113. 2013
  3. pmc Acute graft versus host disease after orthotopic liver transplantation
    Inga Mandac Rogulj
    University of Zagreb School of Medicine, University Hospital Merkur, Zagreb, Croatia
    J Hematol Oncol 5:50. 2012
  4. pmc Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS
    H Joachim Deeg
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109 1024, USA
    Blood 120:1398-408. 2012
  5. pmc Current status of allogeneic hematopoietic cell transplantation for MDS
    Feng Xu
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Curr Pharm Des 18:3215-21. 2012
  6. pmc Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: the past decade
    Ekapun Karoopongse
    Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, 1100 Fairview Avenue N, Seattle, WA 98109 1024, USA
    Expert Rev Clin Immunol 8:373-81. 2012
  7. ncbi request reprint Impact of chronic GVHD on late complications after hematopoietic cell transplantation
    H Joachim Deeg
    Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Seattle, WA 98109 1024, USA
    Hematology 10:245-9. 2005
  8. ncbi request reprint Allogeneic hematopoietic stem cell transplantation for myelofibrosis
    H Joachim Deeg
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1 100, PO Box 19024, Seattle, WA 98109 1024, USA
    Blood 102:3912-8. 2003
  9. pmc Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy
    H Joachim Deeg
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Mail Stop D1 100, PO Box 19024, Seattle, WA 98109 1024, USA
    Blood 108:1485-91. 2006
  10. pmc Who is fit for allogeneic transplantation?
    H Joachim Deeg
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 116:4762-70. 2010

Detail Information

Publications95

  1. pmc Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and concurrent lymphoid malignancy
    Z Zimmerman
    Fred Hutchinson Cancer Research Center and University of Washington School of Medicine, Seattle, WA 98109 1024, USA
    Bone Marrow Transplant 47:804-9. 2012
    ..However, the high non-relapse mortality among previously treated patients, even with reduced-intensity conditioning regimens, indicates that new transplant strategies need to be developed...
  2. pmc Effect of intravenous coadministration of human stroma cell lines on engraftment of long-term repopulating clonal myelodysplastic syndrome cells in immunodeficient mice
    X Li
    1 Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA 2 School of Medicine, Jiangnan University, Wuxi, China
    Blood Cancer J 3:e113. 2013
    ..This xenotransplantation model will allow to further dissect signals that control engraftment of MDS cells and should be amenable to in vivo treatment studies...
  3. pmc Acute graft versus host disease after orthotopic liver transplantation
    Inga Mandac Rogulj
    University of Zagreb School of Medicine, University Hospital Merkur, Zagreb, Croatia
    J Hematol Oncol 5:50. 2012
    ..However, success rates have been low, and new approaches are needed...
  4. pmc Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS
    H Joachim Deeg
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109 1024, USA
    Blood 120:1398-408. 2012
    ..Although mortality declined significantly in recent years, novel strategies are needed to overcome the barrier of high-risk cytogenetics...
  5. pmc Current status of allogeneic hematopoietic cell transplantation for MDS
    Feng Xu
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Curr Pharm Des 18:3215-21. 2012
    ..However, post-transplant relapse and graft-versus-host disease remain problems requiring further investigation...
  6. pmc Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: the past decade
    Ekapun Karoopongse
    Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, 1100 Fairview Avenue N, Seattle, WA 98109 1024, USA
    Expert Rev Clin Immunol 8:373-81. 2012
    ..Recent studies show that drugs used in the non-HCT setting may be beneficial in the context of HCT...
  7. ncbi request reprint Impact of chronic GVHD on late complications after hematopoietic cell transplantation
    H Joachim Deeg
    Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Seattle, WA 98109 1024, USA
    Hematology 10:245-9. 2005
  8. ncbi request reprint Allogeneic hematopoietic stem cell transplantation for myelofibrosis
    H Joachim Deeg
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1 100, PO Box 19024, Seattle, WA 98109 1024, USA
    Blood 102:3912-8. 2003
    ..Results with unrelated donors were comparable with those with HLA-identical sibling transplants. Thus, allogeneic hematopoietic cell transplantation offers long-term relapse-free survival for patients with myelofibrosis...
  9. pmc Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy
    H Joachim Deeg
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Mail Stop D1 100, PO Box 19024, Seattle, WA 98109 1024, USA
    Blood 108:1485-91. 2006
    ..Thus, low-dose TBI + CY + ATG conditioning resulted in excellent outcome of unrelated transplants in patients with aplastic anemia who had received multiple transfusions...
  10. pmc Who is fit for allogeneic transplantation?
    H Joachim Deeg
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 116:4762-70. 2010
    ..They must be well informed, not only about the transplantation process, but also about expected or potential post-HCT events, including graft-versus-host disease and delayed effects that may become manifest only years after HCT...
  11. ncbi request reprint Transplant strategies for patients with myelodysplastic syndromes
    H Joachim Deeg
    Fred Hutchinson Cancer Research Center and the University of Washington, 1100 Fairview Avenue North, Seattle, WA 98109 1024, USA
    Curr Opin Hematol 13:61-6. 2006
    ..The median patient age at diagnosis, however, is about 70 years, which has limited the application of conventional hematopoietic cell transplantation. In addition, the optimum timing of transplantation remains controversial...
  12. pmc Iron overload, hematopoietic cell transplantation, and graft-versus-host disease
    H Joachim Deeg
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Leuk Lymphoma 50:1566-72. 2009
    ..Whether excess iron contributes to GVHD and whether iron depletion, be it by phlebotomy or chelation, reduces the post-transplantation complication rate and improves transplant outcome is yet to be determined...
  13. ncbi request reprint Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells
    H Joachim Deeg
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, D1 100, PO Box 19024, Seattle, WA 98109 1024, USA
    Leuk Res 28:1177-80. 2004
    ..These data show that a combination of ATG plus etanercept offers effective palliative therapy for unselected patients with MDS. Further trials incorporating these two agents are warranted...
  14. ncbi request reprint Successful engraftment following allogeneic stem cell transplantation in very high-risk patients with busulfan as a single agent
    Joachim Deeg
    Fred Hutchinson Cancer Research Center, USA
    Haematologica 90:1013A. 2005
  15. ncbi request reprint Hemopoietic cell transplantation for the myelodysplastic syndromes
    Bart L Scott
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Arch Immunol Ther Exp (Warsz) 53:297-307. 2005
    ..Autologous stem cell transplantation may be beneficial for selected patients who have obtained complete remissions with conventional chemotherapy...
  16. ncbi request reprint Transplantation and aging
    H Joachim Deeg
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 12:893-8. 2006
  17. pmc How I treat refractory acute GVHD
    H Joachim Deeg
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 109:4119-26. 2007
    ..All patients being treated for GVHD should also receive intensive prophylaxis against infectious complications...
  18. ncbi request reprint The clinical spectrum of acute graft-versus-host disease
    H Joachim Deeg
    Fred Hutchinson Cancer Research Center, Seattle WA 98109 1024, USA
    Semin Hematol 43:24-31. 2006
    ..There is no reliable laboratory test for acute GVHD, and the diagnosis is based on clinical assessment...
  19. ncbi request reprint Optimization of allogeneic transplant conditioning: not the time for dogma
    H J Deeg
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Leukemia 20:1701-5. 2006
    ....
  20. ncbi request reprint Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen
    H Joachim Deeg
    Fred Hutchinson Cancer Research Center and University of Washington School of Medicine, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 12:573-84. 2006
    ....
  21. doi request reprint Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: current status
    H Joachim Deeg
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Arch Immunol Ther Exp (Warsz) 60:31-41. 2012
    ..However, post-transplant relapse and graft-versus-host disease remain problems requiring further instigations...
  22. ncbi request reprint Marrow stroma in MDS: culprit or bystander?
    H Joachim Deeg
    Fred Hutchinson Cancer Research Center, University of Washington, 1100 Fairview Avenue North, D1 100, P O Box 19024, 98109 1024, Seattle, WA, USA
    Leuk Res 26:687-8. 2002
  23. ncbi request reprint Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL
    H J Deeg
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 98:2052-8. 2001
    ..No death was attributed to ABX-CBL. At 6 months after the initiation of ABX-CBL therapy, 26 (44%) patients were surviving. These results are encouraging. Further studies on the use of ABX-CBL in the management of GVHD are warranted...
  24. ncbi request reprint Cytokines in graft-versus-host disease and the graft-versus-leukemia reaction
    H J Deeg
    Fred Hutchinson Cancer Research Center and University of Washington, Seattle 98109 1024, USA
    Int J Hematol 74:26-32. 2001
    ..Application of the principles of cytokine signaling to the clinical setting may necessitate new trial design structures that take into consideration donor and host characteristics as well as the kinetics of GVHD development...
  25. ncbi request reprint Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation
    H J Deeg
    Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle 98109 1024, USA
    Biol Blood Marrow Transplant 7:208-15. 2001
    ..As in previous studies, patient age and pretransplantation disease duration remain important prognostic factors...
  26. ncbi request reprint Hematopoietic stem cell transplantation in patients with myelodysplastic syndrome
    H J Deeg
    Fred Hutchinson Cancer Research Center and the University of Washington, 1100 Fairview Avenue North, D1 100, P O Box 19024, Seattle, WA 98109 1024, USA
    Leuk Res 24:653-63. 2000
    ..Treatment-related morbidity and mortality, in particular after allogeneic transplantation, remain challenges that need to be addressed with innovative approaches...
  27. ncbi request reprint Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome
    H Joachim Deeg
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 100:1201-7. 2002
    ..Although there was still considerable nonrelapse morbidity and mortality, the present regimen was used successfully even in patients older than 60 years of age...
  28. ncbi request reprint Negative regulators of hemopoiesis and stroma function in patients with myelodysplastic syndrome
    H J Deeg
    Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, and Hematologics, Seattle 98109 1024, USA
    Leuk Lymphoma 37:405-14. 2000
    ..However, differentiation into mature cells is inhibited by negative signals originating from accessory or abnormal hemopoietic precursors in the non-adherent marrow fraction...
  29. ncbi request reprint Hemopoietic stem cell transplantation for myelodysplastic syndrome
    H J Deeg
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Curr Opin Oncol 12:116-20. 2000
    ..High treatment-related morbidity and mortality rates, particularly after allogeneic transplantation, remain challenges that must be addressed with innovative approaches...
  30. ncbi request reprint New strategies for prevention and treatment of graft-versus-host disease and for induction of graft-versus-leukemia effects
    H Joachim Deeg
    Fred Hutchinson Cancer Research Center and University of Washington, Seattle, Washington 98109 1024, USA
    Int J Hematol 77:15-21. 2003
    ....
  31. ncbi request reprint Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age
    H J Deeg
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 95:1188-94. 2000
    ..These data indicate that BMT can be carried out successfully in patients with MDS who are older than 55 years of age. (Blood. 2000;95:1188-1194)..
  32. ncbi request reprint Myeloablation by intravenous busulfan and hematopoietic reconstitution with autologous marrow in a canine model
    H J Deeg
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 5:316-21. 1999
    ..However, factors other than absorption influence the AUC, and individualization of dosing may be required even with intravenous administration of the drug...
  33. ncbi request reprint Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation
    Paul J Martin
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 10:552-60. 2004
    ....
  34. pmc Longitudinal assessment of morbidity and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation: retrospective analysis of a multicenter phase III study
    Fabrizio Carnevale-Schianca
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Biol Blood Marrow Transplant 15:749-56. 2009
    ..The difficulty of demonstrating clinical benefits from objective parameters, such as survival and morbidity, and the subjectivity of grading acute GVHD emphasize the need for blinded assessments in clinical trials of GVHD prevention...
  35. ncbi request reprint Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long-term follow-up
    Christoph Kahl
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Br J Haematol 130:747-51. 2005
    ..Six patients developed cancer: one fatal lymphoma and five carcinomas (all five patients are now free of cancer). Survival was 88%. The regimen appeared well tolerated and effective in heavily pretreated patients with aplastic anaemia...
  36. pmc Donor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation
    Marcello Rotta
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Blood 115:1288-95. 2010
    ..009). These results suggest that donor statin treatment may be a promising strategy to prevent severe acute GVHD without compromising immunologic control of the underlying malignancy...
  37. pmc Hematopoietic stem cell transplantation for MDS
    Matthias Bartenstein
    Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, Seattle, WA 98109 1024, USA
    Hematol Oncol Clin North Am 24:407-22. 2010
    ..However, posttransplant relapse and graft-versus-host disease (GVHD) remain problems and further investigations are needed...
  38. ncbi request reprint Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone
    Sibel Koc
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 100:48-51. 2002
    ....
  39. ncbi request reprint A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation
    Richard A Nash
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 11:495-505. 2005
    ..Although a significant improvement in the prevention of GVHD was not suggested, compared with CSP and MTX, MMF in combination with CSP could be considered in cases in which MTX is contraindicated...
  40. ncbi request reprint Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older
    Herschel Wallen
    Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington, 1100 Fairview Ave N, D3 100, Seattle, WA 98109, USA
    J Clin Oncol 23:3439-46. 2005
    ..To evaluate outcomes of ablative allogeneic hematopoietic cell transplantation (HCT) in older patients with hematologic malignancies...
  41. ncbi request reprint Curative therapy of advanced essential thrombocythemia or polycythemia vera by hemopoietic stem cell transplantation
    Uwe Platzbecker
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Leuk Lymphoma 43:1409-14. 2002
    ..With a median follow-up of 41 (range 5-116) months after transplant, survival at 3 years is 64%. These data provide evidence that HSCT can be a curative treatment for patients with advanced PV and ET...
  42. ncbi request reprint Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia
    Daniella M B Kerbauy
    Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 13:355-65. 2007
    ..04), and decreased comorbidity score (P = .03) remained statistically significant for improved survival. Our findings show that hematopoietic cell transplantation offers potentially curative treatment for patients with ICMF, PV, or ET...
  43. ncbi request reprint NOD/SCID mice transplanted with marrow from patients with myelodysplastic syndrome (MDS) show long-term propagation of normal but not clonal human precursors
    Ana I Benito
    Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, D1 100, P O Box 19024, Seattle, WA 98109 1204, USA
    Leuk Res 27:425-36. 2003
    ..This model may allow identification of factors relevant for sustaining or expanding clonal precursors...
  44. ncbi request reprint Regression of myelofibrosis and osteosclerosis following hematopoietic cell transplantation assessed by magnetic resonance imaging and histologic grading
    George E Sale
    Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Department of Medicine, Seattle Cancer Care Alliance, Seattle, Washington, USA
    Biol Blood Marrow Transplant 12:1285-94. 2006
    ..In patients undergoing HCT, MRI accurately reflects response or progression of marrow disease...
  45. pmc Transplantation of allogeneic T cells alters iron homeostasis in NOD/SCID mice
    Steven Bair
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 113:1841-4. 2009
    ..These findings suggest that alloreactive T cell-dependent signals induced dysregulation of intestinal iron absorption, which contributed to liver iron overload after HCT...
  46. ncbi request reprint Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality
    Jeannine S McCune
    Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98195, USA
    Biol Blood Marrow Transplant 13:853-62. 2007
    ..Alternative strategies, such as administering i.v. busulfan or CY before BU, should be explored...
  47. ncbi request reprint Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome
    Bart L Scott
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 11:65-73. 2005
    ..Further studies that randomize patients to IC versus no IC need to appropriately address the possible beneficial effect of IC...
  48. ncbi request reprint Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia
    Daniella M B Kerbauy
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 11:713-20. 2005
    ..D. Anderson prognostic score. The data suggest that patients with few or no comorbidities and those who undergo transplantation earlier in the disease course have the highest probability of successful outcome after allogeneic HCT...
  49. ncbi request reprint Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality
    Manuel Jurado
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 8:161-9. 2002
    ..Future trials should explore the efficacy and tolerability of reduced-intensity conditioning regimens...
  50. ncbi request reprint Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation
    Denise A Wells
    HematoLogics, Inc, 113 1st Avenue N, Seattle, WA 98109, USA
    Blood 102:394-403. 2003
    ..01, P =.02, and P =.03, respectively). These data suggest that FCSS is useful in assessing marrows for diagnosis of MDS and in determining the prognostic outcome in patients with this disorder...
  51. pmc NF-kappaB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs)
    Daniella M B Kerbauy
    Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, D1 100, PO Box 19024, Seattle, WA, 98109 1024, USA
    Blood 106:3917-25. 2005
    ..However, the data also suggest that combinations of ATO with agents that interfere with other pathways, such as FLIP autoamplification via NF-kappaB, may have considerable therapeutic activity...
  52. pmc Transferrin fails to provide protection against Fas-induced hepatic injury in mice with deletion of functional transferrin-receptor type 2
    Vladimir Lesnikov
    Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, D1 100, P O Box 19024, Seattle, WA 98109 1024, USA
    Apoptosis 13:1005-12. 2008
    ..Both apoptotic Fas responses and cytoprotective effects of Tf were associated with significant shifts in plasma iron levels, which quantitatively differed between male and female mice...
  53. pmc Hematopoietic cell transplantation for patients with myelodysplastic syndromes (MDS): when, how and for whom?
    Mario Marcondes
    Fred Hutchinson Cancer Research Center and the University of Washington, 1100 Fairview Avenue North, D1 100, PO Box 19024, Seattle, WA 98109 1024, USA
    Best Pract Res Clin Haematol 21:67-77. 2008
    ..However, prospective randomized trials are needed to determine the role of pre-HCT chemotherapy and the type of transplant conditioning regimen best suited for a given patient...
  54. ncbi request reprint Duration of immunosuppressive treatment for chronic graft-versus-host disease
    Betty L Stewart
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, PO Box 19024, Seattle, WA 98109, USA
    Blood 104:3501-6. 2004
    ..After the dose of prednisone was taken into account, progressive onset was not associated with an increased risk of nonrelapse mortality...
  55. pmc Stroma-dependent apoptosis in clonal hematopoietic precursors correlates with expression of PYCARD
    Andrew J Mhyre
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 113:649-58. 2009
    ..These data indicate that stroma may convey not only protective effects on hematopoietic cells, but, dependent upon the milieu, may also facilitate apoptosis...
  56. ncbi request reprint Hematopoietic cell transplantation for adult patients with myelodysplastic syndromes and myeloproliferative disorders
    Martin Benesch
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1 100, PO Box 19024, Seattle, WA 98109 1024, USA
    Mayo Clin Proc 78:981-90. 2003
    ..Outcome of patients with treatment-related MDS or with relapse after transplantation remains poor. At present, no definite conclusions can be made with regard to reduced-intensity transplantation regimens...
  57. pmc The helix-loop-helix transcription factor TWIST is dysregulated in myelodysplastic syndromes
    Xiang Li
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Blood 116:2304-14. 2010
    ..These data suggest role for dysregulation of TWIST in the pathophysiology of MDS. Conceivably, TWIST or components in the signaling pathway could serve as therapeutic targets for patients with MDS...
  58. doi request reprint Incidence of myelodysplastic syndromes within a nonprofit healthcare system in western Washington state, 2005-2006
    Anneclaire J De Roos
    Public Health Sciences Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, Seattle, WA 98109 1024, USA
    Am J Hematol 85:765-70. 2010
    ....
  59. pmc Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes
    Marco Mielcarek
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 113:2888-94. 2009
    ..We conclude that initial treatment with low-dose glucocorticoids for patients with grades I-II GVHD did not compromise disease control or mortality and was associated with decreased toxicity...
  60. pmc Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome
    John M Pagel
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Blood 114:5444-53. 2009
    ..This study was registered at www.clinicaltrials.gov as #NCT00008177...
  61. pmc No telomere shortening in marrow stroma from patients with MDS
    A Mario Marcondes
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Ann Hematol 88:623-8. 2009
    ....
  62. ncbi request reprint A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease
    Paul A Carpenter
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, USA
    Blood 99:2712-9. 2002
    ..Visilizumab is well tolerated and has activity in advanced GVHD. A phase 2 study incorporating preemptive therapy for PTLD is warranted to determine the efficacy of visilizumab in GVHD...
  63. pmc Basal cell skin cancer after total-body irradiation and hematopoietic cell transplantation
    Jeffrey L Schwartz
    Department of Radiation Oncology, The University of Washington Medical Center, Seattle, Washington 98195 6069, USA
    Radiat Res 171:155-63. 2009
    ....
  64. ncbi request reprint Targeted busulfan and cyclophosphamide as compared to busulfan and TBI as preparative regimens for transplantation in patients with advanced MDS or transformation to AML
    Bart Scott
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Leuk Lymphoma 45:2409-17. 2004
    ..New concepts of conditioning regimens are needed which reduce toxicity without increasing the risk of relapse...
  65. ncbi request reprint Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease
    Terry Furlong
    Fred Hutchinson Cancer Research Center, and the Department of Medicine, University of Washington, Seattle 98109 1024, USA
    Biol Blood Marrow Transplant 8:206-12. 2002
    ..Fifty-three patients (51%) remain alive at 129-1883 days after transplantation. These results suggest that PUVA can be an effective therapy for steroid-resistant acute GVHD of the skin...
  66. doi request reprint Myelodysplastic syndromes
    Bart L Scott
    Fred Hutchinson Cancer Research Center and University of Washington School of Medicine, Seattle, Washington 98109, USA
    Annu Rev Med 61:345-58. 2010
    ..The median age of diagnosis is 72 and the median survival is 2.5 years. Lenalidomide, azacitidine, and decitabine are all FDA-approved agents to treat MDS; however, the only potential cure for MDS remains stem cell transplantation...
  67. pmc Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept
    Bart L Scott
    Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, Seattle, WA 98109 1024, USA
    Br J Haematol 148:944-7. 2010
    ..The overall response rate was 72%; median duration of response was not reached at 2 years. Marrow response rates and duration were improved with azacitidine + etanercept compared to azacitidine alone...
  68. ncbi request reprint Flow cytometric detection of nonneoplastic antigenic polymorphisms of donor origin after allogeneic marrow transplant: a report of two cases
    Linlin Wang
    HematoLogics, Seattle, WA 98109, USA
    Am J Clin Pathol 122:135-40. 2004
    ..The distinction of these phenotypic abnormalities from neoplastic changes such as secondary myelodysplasias or relapse of original disease is important in posttransplantation monitoring of hematopoietic diseases...
  69. pmc Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study
    Bart L Scott
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Br J Haematol 149:706-10. 2010
    ..Thus, combination therapy with ATG and etanercept was active and safe in patients with MDS...
  70. ncbi request reprint Prevention of Fas-mediated hepatic failure by transferrin
    Vladimir A Lesnikov
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Lab Invest 84:342-52. 2004
    ..In conclusion, the data suggest that Tf has broader functions than previously recognized and may serve as a cytoprotective agent...
  71. pmc Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation
    Paul J Martin
    Fred Hutchinson Cancer Research Center D2 100, PO Box 19024, Seattle, WA 98109 1024, USA
    J Clin Oncol 28:1011-6. 2010
    ..Further effort is needed to reduce the burden of disease and treatment-related complications in this population...
  72. pmc Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome
    Bart L Scott
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Blood 112:2681-6. 2008
    ..7; P = .02). This analysis confirmed that FCSS scores are predictive of posttransplantation outcomes in patients with MDS even after adjusting for risk factors such as marrow myeloblast percentage and IPSS score...
  73. pmc Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences
    Mohamed L Sorror
    Fred Hutchinson Cancer Research Center FHCRC, Seattle, WA 98109 1024, USA
    Blood 110:4606-13. 2007
    ..98, P = .94). The HCT-CI is a sensitive and informative tool for comparing trial results at different institutions. Inclusion of comorbidity data in HCT trials provides valuable, independent information...
  74. pmc Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT-Late Effect Working Party
    Debra L Friedman
    Fred Hutchinson Cancer Research Center, University of Washington, Seattle 98109, USA
    Blood 111:939-44. 2008
    ..Hazard for death associated with breast cancer was 2.5 (95% CI: 1.1-5.8). We conclude that female survivors of allogeneic HCT are at increased risk of breast cancer and should be educated about the need for regular screening...
  75. ncbi request reprint Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation
    Mohamed L Sorror
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    J Clin Oncol 25:4246-54. 2007
    ..Refined risk stratification is required to design prospective trials...
  76. ncbi request reprint Tumour necrosis factor-induced gene expression in human marrow stroma: clues to the pathophysiology of MDS?
    Derek L Stirewalt
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Br J Haematol 140:444-53. 2008
    ..Additional studies will be required to determine which of these signals are critical for the induction of apoptosis in the malignant clones. Those insights, in turn, may point the way to novel therapeutic approaches...
  77. ncbi request reprint Evidence of donor-derived hematologic malignancies after hematopoietic stem cell transplantation
    Olga Sala-Torra
    Division of Clinical Research, Program in Genetics and Genomics, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Biol Blood Marrow Transplant 12:511-7. 2006
    ..Donors in the first group were significantly older than donors in the second group. A more systematic examination of the prevalence and biology of donor malignancies would merit study...
  78. ncbi request reprint Marrow fibrosis as a risk factor for posttransplantation outcome in patients with advanced myelodysplastic syndrome or acute myeloid leukemia with multilineage dysplasia
    Bart L Scott
    Department of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 13:345-54. 2007
    ....
  79. pmc Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors
    Terry Furlong
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, WA 98109 1024, USA
    Biol Blood Marrow Transplant 14:531-7. 2008
    ..In these studies, the addition of sirolimus to regimens containing a calcineurin inhibitor and methotrexate appeared to cause toxicity and provided no detectable improvement in preventing GVHD...
  80. pmc Pretransplant neutropenia is associated with poor-risk cytogenetic features and increased infection-related mortality in patients with myelodysplastic syndromes
    Bart L Scott
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 14:799-806. 2008
    ..94 [1.0-3.8], P = .05), but not for overall mortality or NRM. We propose that intensified strategies to prevent infections should be implemented in MDS patients with preexisting neutropenia who undergo HSCT...
  81. ncbi request reprint A population-based study of survival in patients with secondary myelodysplastic syndromes (MDS): impact of type and treatment of primary cancers
    Anneclaire J De Roos
    Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Department of Epidemiology, University of Washington, Seattle, WA 98109 1024, USA
    Cancer Causes Control 18:1199-208. 2007
    ..Clinical observations suggest a worse prognosis for secondary than for primary MDS, but differences in survival have not been studied in a general population sample...
  82. ncbi request reprint Myelodysplastic syndrome
    Shinji Nakao
    Cellular Transplantation Biology, Division of Cancer Medicine, Kanazawa University Graduate School of Medical Science, 13 1 Takaramachi, Kanazawa City, Ishikawa 920 8641, Japan
    Int J Hematol 82:412-6. 2005
  83. ncbi request reprint Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells
    Martin Bornhauser
    Medizinische Klinik und Poliklinik I, Universitatsklinikum Carl Gustav Carus, Fetscherstrasse 74, 01307 Dresden, Germany
    Blood 102:820-6. 2003
    ..Based on these encouraging results, further studies of fludarabine and targeted busulfan are warranted in standard-risk patients...
  84. ncbi request reprint Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and
    Ruben A Mesa
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 31:737-40. 2007
    ....
  85. ncbi request reprint Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program
    Hugo Castro-Malaspina
    Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Blood 99:1943-51. 2002
    ..The observations made in this study should facilitate the design of prospective trials aimed at improving the results of unrelated donor stem cell transplantation for MDS...
  86. ncbi request reprint Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation
    Wendy Leisenring
    Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA 98109, USA
    J Clin Oncol 24:1119-26. 2006
    ..To evaluate the incidence of and risk factors for basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) in survivors of hematopoietic cell transplantation (HCT)...
  87. ncbi request reprint Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation
    Paul J Martin
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 10:320-7. 2004
    ..A high diagnostic sensitivity and increased awareness that gut GVHD can occur without skin involvement account for the increased incidence of acute GVHD at our center...
  88. ncbi request reprint Control of hematopoiesis and apoptosis in MDS: more than FLIPing the coin
    Andrew J Mhyre
    Leuk Res 31:747-9. 2007
  89. pmc Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic d
    Chunkang Chang
    Department of Hematology, Shanghai Sixth People s Hospital, Shanghai Jiaotong University, Shanghai, People s Republic of China
    Blood 110:1379-87. 2007
    ..The data suggest that overall inferior outcome in patients with secondary MDS/tAML was related to the frequency of high-risk cytogenetics. For both cohorts, transplantation outcomes improved over the time interval studied...
  90. ncbi request reprint Hematopoietic stem cell transplantation for myelofibrosis
    Koen Van Besien
    Section of Hematology Oncology, University of Chicago, IL 60637, USA
    Semin Oncol 32:414-21. 2005
    ..Finally, autologous transplantation has also been evaluated as a potential treatment approach. This procedure is unlikely to be curative, but might have a palliative role...
  91. ncbi request reprint Fanconi anemia type C-deficient hematopoietic cells are resistant to TRAIL (TNF-related apoptosis-inducing ligand)-induced cleavage of pro-caspase-8
    Uwe Platzbecker
    University Hospital Carl Gustav Carus, Dresden, Germany
    Exp Hematol 32:815-21. 2004
    ..We investigated whether a new member of the TNF family, TRAIL (TNF-related apoptosis-inducing ligand), would similarly trigger preferential apoptotic cell death in FA phenotype cells...
  92. ncbi request reprint Twenty-year follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia
    Mohamed L Sorror
    Biol Blood Marrow Transplant 11:814-5. 2005
  93. pmc Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function
    A Mario Marcondes
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Department of Pathology, and Division of Oncology, University of Washington, Seattle, WA 98195
    Proc Natl Acad Sci U S A 105:2865-70. 2008
    ..We propose that IL-32 is a marrow stromal marker that distinguishes patients with MDS and CMML. Furthermore, IL-32 appears to contribute to the pathophysiology of MDS and may be a therapeutic target...
  94. ncbi request reprint Re: Twenty-year follow-up in patients with aplastic anemia given marrow grafts from HLA-identical siblings and randomized to receive methotrexate/cyclosporine or methotrexate alone for prevention of graft-versus-host disease
    Mohamed L Sorror
    Biol Blood Marrow Transplant 11:567-8. 2005
  95. ncbi request reprint Hematopoietic cell transplantation for chronic myeloproliferative disorders
    William Tse
    Division of Hematology Oncology, Ireland Cancer Center, University Hospitals of Cleveland, Case Western Reserve University School of Medicine, Cleveland, OH, USA
    Arch Immunol Ther Exp (Warsz) 54:375-80. 2006
    ....

Research Grants10

  1. Cell Death and Clonal Survival in Myelodysplastic Syndr*
    H Deeg; Fiscal Year: 2007
    ..To achieve these objectives, we must better understand the underlying mechanisms of MDS and thereby identify ways by which the disease process can be arrested, progression prevented, and the disease hopefully be cured. ..
  2. NOVEL THERAPEUTIC STRATEGIES IN MYELODYSPLASTIC SYNDROME
    H Deeg; Fiscal Year: 2000
    ..Optimization of therapy, in turn, should reduce morbidity and mortality associated with MDS and improve the quality of life of patients with MDS. ..
  3. WT1 Expression in Patients with MDS Treated with ATG an*
    H Deeg; Fiscal Year: 2007
    ....
  4. Cell Death and Clonal Survival in Myelodysplastic Syndr*
    H Deeg; Fiscal Year: 2006
    ..To achieve these objectives, we must better understand the underlying mechanisms of MDS and thereby identify ways by which the disease process can be arrested, progression prevented, and the disease hopefully be cured. ..
  5. Cell Death and Clonal Survival in Myelodysplastic Syndr*
    H Deeg; Fiscal Year: 2005
    ..To achieve these objectives, we must better understand the underlying mechanisms of MDS and thereby identify ways by which the disease process can be arrested, progression prevented, and the disease hopefully be cured. ..
  6. NOVEL THERAPEUTIC STRATEGIES IN MYELODYSPLASTIC SYNDROME
    H Deeg; Fiscal Year: 2003
    ..Optimization of therapy, in turn, should reduce morbidity and mortality associated with MDS and improve the quality of life of patients with MDS. ..
  7. NOVEL THERAPEUTIC STRATEGIES IN MYELODYSPLASTIC SYNDROME
    H Deeg; Fiscal Year: 2002
    ..Optimization of therapy, in turn, should reduce morbidity and mortality associated with MDS and improve the quality of life of patients with MDS. ..
  8. NOVEL THERAPEUTIC STRATEGIES IN MYELODYSPLASTIC SYNDROME
    H Deeg; Fiscal Year: 2001
    ..Optimization of therapy, in turn, should reduce morbidity and mortality associated with MDS and improve the quality of life of patients with MDS. ..
  9. Hematopoietic Cell Transplantation and Iron Overload
    H Joachim Deeg; Fiscal Year: 2010
    ....